Log in or Sign up for Free to view tailored content for your specialty!
Chronic Hepatitis News
People with HBV, HIV coinfection at risk for hepatitis D ‘superinfection’
Patients with HIV and hepatitis B coinfection are at an increased risk for hepatitis D, which is associated with an increased risk of liver-related complications and mortality, researchers found.
Hispanic patients with alcohol use disorder face greater odds for hepatitis, cirrhosis
Hispanic patients hospitalized for alcohol use disorder were more likely to develop alcohol-associated hepatitis, decompensated cirrhosis and related complications compared with non-Hispanic white patients, according to published data.
CDC: Heplisav-B joins recommended HBV vaccine options for pregnant patients
Data from a postlicensure study support the CDC’s recommendation that Heplisav-B can now be administered to pregnant persons needing hepatitis B vaccination, as its use did not appear to increase risk for major birth defects or miscarriage.
Log in or Sign up for Free to view tailored content for your specialty!
HCC incidence nearly 5-times higher among HBV, HDV coinfected patients with cirrhosis
Incidence of hepatocellular carcinoma was significantly higher among cirrhotic patients coinfected with hepatitis B and D viruses compared with those with HBV alone, with researchers suggesting HDV “plays a direct role” in HCC occurrence.
‘Only one in six’ veterans with chronic HBV finish HDV testing despite severe disease risk
Among veterans with chronic hepatitis B virus infection, rates of hepatitis D virus testing were low and those with concurrent infection were at greater risk for cirrhosis and hepatic decompensation, according to study results.
VIDEO: Combination tobevibart, elebsiran induces ‘rapid virologic suppression’ in HDV
SAN DIEGO — Combination tobevibart and elebsiran led to “profound and rapid virologic suppression” as well as normalization of alanine aminotransferase at week 24 in chronic hepatitis D virus infection, according to preliminary data.
Resuming antiviral therapy after withdrawal does not affect HBsAG seroclearance in HBV
SAN DIEGO — Retreatment with nucleos(t)ide analogue therapy for relapse after withdrawal did not affect hepatitis B surface antigen seroclearance among patients with chronic HBV infection, according to a researcher at The Liver Meeting.
VIDEO: Simplified screening, treatment strategies critical in HBV
PHILADELPHIA — Paul Kwo, MD, professor of medicine at Stanford University, speaks with Healio about presentations investigating the undertreatment of hepatitis B.
HBeAg-seroconversion in childhood among predictors of functional cure of chronic HBV
Hepatitis B e-antigen seroconversion in childhood and low hepatitis B surface antigen titers after seroconversion independently predicted functional cure in chronic HBV-infected patients followed from childhood through adulthood.
Even with HCV cure, surveillance for portal hypertension, HCC ‘should be mandatory’
Despite achieving cure with direct-acting antivirals, patients with chronic hepatitis C virus-related decompensated cirrhosis remain at risk for progression of portal hypertension, further decompensation and hepatocellular carcinoma.
-
Headline News
Medicare selects 15 drugs for second round of price negotiations, including semaglutide
January 17, 20252 min read -
Headline News
Q&A: Physicians can help patients with respiratory diseases prepare for wildfires
January 17, 20253 min read -
Headline News
‘Now is not the time to lose momentum’ in the fight against STIs
January 10, 20259 min read
-
Headline News
Medicare selects 15 drugs for second round of price negotiations, including semaglutide
January 17, 20252 min read -
Headline News
Q&A: Physicians can help patients with respiratory diseases prepare for wildfires
January 17, 20253 min read -
Headline News
‘Now is not the time to lose momentum’ in the fight against STIs
January 10, 20259 min read